| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 13,070 | 13,900 | 12,270 | 11,180 | 9,660 |
| Sales Growth | -5.97% | +13.28% | +9.75% | +15.74% | +3.21% |
| Net Income | -910 | 10 | -870 | 300 | -900 |
| Net Income Growth | -9,200.00% | +101.15% | -390.00% | +133.33% | -140.91% |
Radnostix Inc (INIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Radnostix Inc. manufactures a wide range of radioisotope focused products. The company manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. It also manufactures Cobalt-60 sealed source products. Radnostix Inc., formerly known as International Isotopes Inc., is based in IDAHO FALLS, Idaho.
Fiscal Year End Date: 12/31